On Saturday, December 4, 2021, starting at 10:00 p.m. EST we will be launching the New FAST Graphs. This may cause temporary interruptions. We are sorry for any inconvenience this may cause.

Menu

pharmaceutical

Cardinal Health: A Dividend Aristocrat the Risk Is Already Priced In-Part 2 of 7

2017-11-22

Research Articles

Introduction As a value investor, I am totally cognizant of the reality that attractively valued bargains are hard to find in a strong bull market.  Moreover, as an experienced value investor I clearly understand that low valuations in a raging bull market are usually associated with issues and challenges sometimes real, sometimes imaginary.  The key […]

Pfizer Inc. Invest For Attractive Valuation and The 4% Dividend Yield

2017-02-22

Research Articles

Investment Thesis Pfizer Inc (PFE) is one of the world’s largest pharmaceutical firms with sales exceeding $50 billion.  The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%.  Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio […]

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on Fastgraphs.com constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on Fastgraphs.com. Fastgraphs.com is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.